Vistagen Therapeutics Inc (NASDAQ: VTGN) started the day on Wednesday, with a price increase of 3.46% at $2.69, before settling in for the price of $2.60 at the close. Taking a more long-term approach, VTGN posted a 52-week range of $2.48-$5.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 89.88% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 43.79%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -20.56%. This publicly-traded company’s shares outstanding now amounts to $27.03 million, simultaneously with a float of $25.02 million. The organization now has a market capitalization sitting at $74.90 million. At the time of writing, stock’s 50-day Moving Average stood at $2.95, while the 200-day Moving Average is $3.79.
Vistagen Therapeutics Inc (VTGN) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Vistagen Therapeutics Inc’s current insider ownership accounts for 10.15%, in contrast to 45.55% institutional ownership.
Vistagen Therapeutics Inc (VTGN) Earnings and Revenue Records
Vistagen Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -20.56% and is forecasted to reach -1.90 in the upcoming year.
Vistagen Therapeutics Inc (NASDAQ: VTGN) Trading Performance Indicators
Let’s observe the current performance indicators for Vistagen Therapeutics Inc (VTGN). It’s Quick Ratio in the last reported quarter now stands at 13.29. The Stock has managed to achieve an average true range (ATR) of 0.15. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 85.11.
In the same vein, VTGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.34, a figure that is expected to reach -0.51 in the next quarter, and analysts are predicting that it will be -1.90 at the market close of one year from today.
Technical Analysis of Vistagen Therapeutics Inc (VTGN)
If we take a close look at the recent performances of Vistagen Therapeutics Inc (NASDAQ: VTGN), its last 5-days Average volume was 0.22 million that shows progress from its year to date volume of 0.2 million. During the previous 9 days, stock’s Stochastic %D was recorded 49.49% While, its Average True Range was 0.15.
Raw Stochastic average of Vistagen Therapeutics Inc (VTGN) in the period of the previous 100 days is set at 12.14%, which indicates a major fall in contrast to 27.81% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 48.18% that was higher than 46.29% volatility it exhibited in the past 100-days period.
